Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles

Journal of Nanoparticle Research

Volumn 15, Issue 5, 2013, Pages

  Chuan, Junlan ^a,d   Li, Yanzhen ^b   Yang, Likai ^a   Sun, Xun ^a   Zhang, Qiang ^c   Gong, Tao ^a,b   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Alveolar epithelial type II cells; Alveolar macrophages; Rifampicin; Solid lipid nanoparticles

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACROPHAGES; NANOPARTICLES; TARGETED DRUG DELIVERY;

ALVEOLAR MACROPHAGES; CONFOCAL LASER SCANNING MICROSCOPY; FLUORESCENT INTENSITY; PULMONARY ADMINISTRATIONS; RIFAMPICIN; SOLID LIPID NANOPARTICLE (SLN); TUBERCULOSIS INFECTION; TYPE II;

CONTROLLED DRUG DELIVERY;

RIFAMPICIN; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; EPITHELIUM CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG ALVEOLUS MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84875905763     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-1634-1     Document Type: Article

References (36)

1. Aderem A, Underhill DM (1999) Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 17:593-623. doi: 10.1146/annurev.immunol.17.1.593
2. Albrecht C, Scherbart AM, Berlo Dv, Braunbarth CM, Schins RPF, Scheel J (2009) Evaluation of cytotoxic effects and oxidative stress with hydroxyapatite dispersions of different physicochemical properties in rat NR8383 cells and primary macrophages. Toxicol In Vitro 23(3):520-530. doi: 10.1016/j.tiv.2009.01. 005
3. Armstrong JA, Arcy Hart PD (1972) Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 134(3):713-740
4. Bivas-Benita M, Zwier R, Junginger HE, Borchard G (2005) Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 61(3):214-218
5. Bothamley G (2001) Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 24:553-565
6. Briones E, Isabel Colino C, Lanao JM (2008) Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Controlled Release 125(3):210-227. doi: 10.1016/j.jconrel.2007.10.027
7. Chellat F, Merhi Y, Moreau A, Yahia LH (2005) Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 26(35):7260-7275. doi: 10.1016/j.biomaterials.2005.05.044
8. Chen J, Chen Z, Narasaraju T, Jin N, Liu L (2004) Isolation of highly pure alveolar epithelial type I and type II cells from rat lungs. Lab Invest 84(6):727-735
9. Chono S, Tanino T, Seki T, Morimoto K (2006) Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 14(8):557-566. doi: 10.1080/10611860600834375
10. Chono S, Tanino T, Seki T, Morimoto K (2007) Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol 59(1):75-80. doi: 10.1211/jpp.59.1.0010
11. Chono S, Tanino T, Seki T, Morimoto K (2008) Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Controlled Release 127(1):50-58. doi: 10.1016/j.jconrel.2007.12.011
12. Chuan JL, Gong T, Sun X, Zhang Z (2011) Preparation of rifampicin-solid lipid nanoparticles and evaluation of their cell specificity. West China J Pharm Sci 26(3):223-225
13. Conner SD, Schmid SL (2003) Regulated portals of entry into the cell. Nature 422(6927):37-44. doi: 10.1038/nature01451
14. Crofton John (1960) Drug treatment of tuberculosisl. BMJ 2:370-373
15. Edelson JD, Shannon JM, Mason RJ (1988) Alkaline phosphatase: a marker of alveolar type II cell differentiation. Am J Respir Crit Care Med 138(5):1268-1275. doi: 10.1164/ajrccm/138.5.1268
16. Ferrari G, Langen H, Naito M, Pieters J (1999) A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 97(4):435-447. doi: 10.1016/s0092-8674(00)80754-0
17. He C, Hu Y, Yin L, Tang C, Yin C (2010) Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13):3657-3666. doi: 10.1016/j.biomaterials.2010. 01.065
18. Hirota K, Hasegawa T, Hinata H, Ito F, Inagawa H, Kochi C, Soma G-I, Makino K, Terada H (2007) Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Controlled Release 119(1):69-76. doi: 10.1016/j.jconrel.2007.01.013
19. Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G-I, Makino K, Terada H (2010) Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Controlled Release 142(3):339-346. doi: 10.1016/j.jconrel.2009.11.020
20. Krist LFG, Kerremans M, Koenen H, Blijleven N, Eestermans IL, Calame W, Meyer S, Beelen RHJ (1995) Novel isolation and purification method permitting functional cytotoxicity studies of macrophages from milky spots in the greater omentum. J Immunol Methods 184(2):253-261. doi: 10.1016/0022-1759(95)00096-s
21. Lawlor C, Kelly C, O'Leary S, O'Sullivan MP, Gallagher PJ, Keane J, Cryan SA (2011) Cellular targeting and trafficking of drug delivery systems for the prevention and treatment of MTb. Tuberculosis 91(1):93-97. doi: 10.1016/j.tube.2010.12.001
22. Li Y-Z, Sun X, Gong T, Liu J, Zuo J, Zhang Z-R (2010) Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res 27(9):1977-1986. doi: 10.1007/s11095-010-0201-z
23. McKinney J, Hoener zu Bentrup K, Munoz-Elias E, Chan WT, Swensonēǵ D, Sacchettinik J (2000) Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406(6797):735-738
24. Nafee N, Schneider M, Schaefer UF, Lehr C-M (2009) Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm 381(2):130-139. doi: 10.1016/j.ijpharm.2009.04.049
25. Natarajan K, Kundu M, Sharma P, Basu J (2011) Innate immune responses to M. tuberculosis infection. Tuberculosis 91(5):427-431. doi: 10.1016/j.tube.2011. 04.003
26. Nguyen L, Pieters J (2005) The Trojan horse: survival tactics of pathogenic mycobacteria in macrophages. Trends Cell Biol 15(5):269-276. doi: 10.1016/j.tcb.2005.03.009
27. Onoshita T, Shimizu Y, Yamaya N, Miyazaki M, Yokoyama M, Fujiwara N, Nakajima T, Makino K, Terada H, Haga M (2010) The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf B 76(1):151-157. doi: 10.1016/j.colsurfb.2009.10.036
28. Pallanza R, Arioli V, Furesz S, Bolzoni G (1967) Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations. Arzneimittelforschung 17(5):529-534
29. Panchagnula R, Sood A, Sharda N, Kaur K, Kaul CL (1999) Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method. J Pharm Biomed Anal 18(6):1013-1020. doi: 10.1016/s0731-7085(98)00112-5
30. Pandey R, Khuller GK (2005) Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85(4):227-234. doi: 10.1016/j.tube.2004.11.003
31. Pandey R, Sharma S, Khuller G (2005) Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 85(5-6):415-420. doi: 10.1016/j.tube.2005.08.009
32. Post M, Smith BT (1988) Histochemical and immunocytochemical identification of alveolar type II epithelial cells isolated from fetal rat lung. Am J Respir Crit Care Med 137(3):525-530. doi: 10.1164/ajrccm/137.3.525
33. Thomas CZ (2003) Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection. Microbes Infect 5(2):159-167. doi: 10.1016/s1286- 4579(02)00083-7
34. Vergne I, Chua J, Singh SB, Deretic V (2004) Cell biology of Mycobacterium tuberculosis phagosome. Annu Rev Cell Dev Biol 20:367-394. doi: 10.1146/annurev.cellbio.20.010403.114015
35. WHO (2010) Global Tuberculosis Control. Geneva
36. Wijagkanalan W, Kawakami S, Takenaga M, Igarashi R, Yamashita F, Hashida M (2008) Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J Controlled Release 125(2):121-130